A study analyzing people living with HIV who transitioned to long‑acting injectable cabotegravir plus rilpivirine revealed marked shifts in monocyte populations and immune activation markers. The research documented changes in innate immune cell composition following the move from daily oral regimens to monthly or bimonthly injectable therapy. Investigators reported altered monocyte subsets and cytokine expression profiles that could influence long-term inflammation, reservoir dynamics and comorbidity risks. The findings were positioned as important for understanding immunologic consequences of depot antiretroviral delivery. Authors noted that while injectable regimens improve adherence and reduce daily pill burden, they may introduce distinct immune-modulatory effects that clinicians and trialists must monitor. The study recommends longitudinal immune phenotyping in larger cohorts and correlation with clinical endpoints. HIV program leads, guideline committees and developers of long‑acting formulations should incorporate immune-monitoring endpoints in future studies to assess whether observed shifts affect clinical outcomes, end-organ disease risk or cure strategies.